Cargando…

Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles

The power and influence of healthcare systems comes largely from the ability to prescribe efficacious medicine. However, medicine can sometimes cause harm rather than bring benefits. Systematically checking patients for the adverse effects of medicines, as listed in manufacturers’ literature, would...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, Sue, Logan, Patricia A., Panes, Gerwyn, Vaismoradi, Mojtaba, Hughes, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165166/
https://www.ncbi.nlm.nih.gov/pubmed/30231573
http://dx.doi.org/10.3390/pharmacy6030102
_version_ 1783359772790095872
author Jordan, Sue
Logan, Patricia A.
Panes, Gerwyn
Vaismoradi, Mojtaba
Hughes, David
author_facet Jordan, Sue
Logan, Patricia A.
Panes, Gerwyn
Vaismoradi, Mojtaba
Hughes, David
author_sort Jordan, Sue
collection PubMed
description The power and influence of healthcare systems comes largely from the ability to prescribe efficacious medicine. However, medicine can sometimes cause harm rather than bring benefits. Systematically checking patients for the adverse effects of medicines, as listed in manufacturers’ literature, would protect patients from iatrogenic harm, but this is rarely undertaken. We argue for the benefits of this approach using the example of the prescription of antipsychotics to older adults. Prescribing antipsychotics to control challenging behaviours associated with dementia is a controversial matter, and regulatory intervention is under discussion. Improved regulatory systems could protect against iatrogenic harm, such as over-sedation, falls, tremor, or drug-induced Parkinsonism. However, measuring the impact and outcomes of regulatory interventions has proved difficult, not least because there are rarely systematic records of all adverse effects of medicines. We indicate how regulatory initiatives to reduce antipsychotic prescribing can be supported by systematic monitoring and documentation of patients’ signs and symptoms of putative adverse drug reactions. Monitoring documentation then provides the rationale and support for professionals’ responses to identified problems. Longitudinal monitoring records would improve understanding of the impact and outcomes of adverse drug reactions (ADRs) on health and wellbeing, and the many costs of ADRs.
format Online
Article
Text
id pubmed-6165166
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61651662018-10-10 Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles Jordan, Sue Logan, Patricia A. Panes, Gerwyn Vaismoradi, Mojtaba Hughes, David Pharmacy (Basel) Discussion The power and influence of healthcare systems comes largely from the ability to prescribe efficacious medicine. However, medicine can sometimes cause harm rather than bring benefits. Systematically checking patients for the adverse effects of medicines, as listed in manufacturers’ literature, would protect patients from iatrogenic harm, but this is rarely undertaken. We argue for the benefits of this approach using the example of the prescription of antipsychotics to older adults. Prescribing antipsychotics to control challenging behaviours associated with dementia is a controversial matter, and regulatory intervention is under discussion. Improved regulatory systems could protect against iatrogenic harm, such as over-sedation, falls, tremor, or drug-induced Parkinsonism. However, measuring the impact and outcomes of regulatory interventions has proved difficult, not least because there are rarely systematic records of all adverse effects of medicines. We indicate how regulatory initiatives to reduce antipsychotic prescribing can be supported by systematic monitoring and documentation of patients’ signs and symptoms of putative adverse drug reactions. Monitoring documentation then provides the rationale and support for professionals’ responses to identified problems. Longitudinal monitoring records would improve understanding of the impact and outcomes of adverse drug reactions (ADRs) on health and wellbeing, and the many costs of ADRs. MDPI 2018-09-18 /pmc/articles/PMC6165166/ /pubmed/30231573 http://dx.doi.org/10.3390/pharmacy6030102 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Discussion
Jordan, Sue
Logan, Patricia A.
Panes, Gerwyn
Vaismoradi, Mojtaba
Hughes, David
Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles
title Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles
title_full Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles
title_fullStr Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles
title_full_unstemmed Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles
title_short Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles
title_sort adverse drug reactions, power, harm reduction, regulation and the adre profiles
topic Discussion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165166/
https://www.ncbi.nlm.nih.gov/pubmed/30231573
http://dx.doi.org/10.3390/pharmacy6030102
work_keys_str_mv AT jordansue adversedrugreactionspowerharmreductionregulationandtheadreprofiles
AT loganpatriciaa adversedrugreactionspowerharmreductionregulationandtheadreprofiles
AT panesgerwyn adversedrugreactionspowerharmreductionregulationandtheadreprofiles
AT vaismoradimojtaba adversedrugreactionspowerharmreductionregulationandtheadreprofiles
AT hughesdavid adversedrugreactionspowerharmreductionregulationandtheadreprofiles